269 related articles for article (PubMed ID: 18597654)
21. Genetic factors in drug metabolism.
Belle DJ; Singh H
Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
[TBL] [Abstract][Full Text] [Related]
22. Advances of molecular clinical pharmacology in gastroenterology and hepatology.
Prandota J
Am J Ther; 2010; 17(5):e137-62. PubMed ID: 19433977
[TBL] [Abstract][Full Text] [Related]
23. Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.
Yoo HD; Lee YB
Arch Pharm Res; 2011 Nov; 34(11):1817-28. PubMed ID: 22139683
[TBL] [Abstract][Full Text] [Related]
24. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.
Stingl JC; Brockmöller J; Viviani R
Mol Psychiatry; 2013 Mar; 18(3):273-87. PubMed ID: 22565785
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics in cancer treatment.
Nagasubramanian R; Innocenti F; Ratain MJ
Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacogenetics and its importance in the clinical].
Lares-Asseff I; Trujillo-Jiménez F
Gac Med Mex; 2001; 137(3):227-36. PubMed ID: 11432091
[TBL] [Abstract][Full Text] [Related]
27. Personalized therapy in pain management: where do we stand?
Stamer UM; Zhang L; Stüber F
Pharmacogenomics; 2010 Jun; 11(6):843-64. PubMed ID: 20504256
[TBL] [Abstract][Full Text] [Related]
28. Ontogeny and drug metabolism in newborns.
Dotta A; Chukhlantseva N
J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
[TBL] [Abstract][Full Text] [Related]
29. Understanding the genetic causes of inter-patient variability. Clinical relevance with focus on cardiovascular drugs.
Ginghină C; Stănescu R; Coman IM; Bărbari L; Popescu BA
Rom J Intern Med; 2007; 45(4):313-9. PubMed ID: 18767405
[TBL] [Abstract][Full Text] [Related]
30. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
Murray M
J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
[TBL] [Abstract][Full Text] [Related]
31. The pharmacogenetics of analgesia.
Stamer UM; Stüber F
Expert Opin Pharmacother; 2007 Oct; 8(14):2235-45. PubMed ID: 17927480
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of opioid pharmacogenetics.
Argoff CE
Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
[TBL] [Abstract][Full Text] [Related]
33. The metabolism of opioid agents and the clinical impact of their active metabolites.
Smith HS
Clin J Pain; 2011; 27(9):824-38. PubMed ID: 21677572
[TBL] [Abstract][Full Text] [Related]
34. [Genetic variation-- important for the clinical effect of opioids?].
Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic-pharmacodynamic relationships for analgesics.
Suri A; Estes KS; Geisslinger G; Derendorf H
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):307-23. PubMed ID: 9266286
[TBL] [Abstract][Full Text] [Related]
36. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
[TBL] [Abstract][Full Text] [Related]
37. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
[TBL] [Abstract][Full Text] [Related]
38. Clinical application of pharmacogenomics.
Ma JD; Lee KC; Kuo GM
J Pharm Pract; 2012 Aug; 25(4):417-27. PubMed ID: 22689709
[TBL] [Abstract][Full Text] [Related]
39. Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?
Ozdemir V; Gunes A; Dahl ML; Scordo MG; Williams-Jones B; Someya T
Pharmacogenomics; 2006 Dec; 7(8):1199-210. PubMed ID: 17184207
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics in palliative care.
Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
